The following table details the trading activities
(stock purchases, stock sales, and stock option exercises)
reported to
the Securities and Exchange Commission (SEC)
by insider Sharp Philip A since year 2005.
The trader's CIK number is 1226295.
At the time of this reporting, Sharp Philip A is the Director of Alnylam Pharmaceuticals, Inc. .
(stock ticker symbol ALNY).
See this page for all insider trading activities at Alnylam Pharmaceuticals, Inc. .
| Trade Date | Symbol | Company Name (Issuer) | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|---|
| 2018-03-13 | ALNY | Alnylam Pharmaceuticals, Inc. | Option Ex | 15,000 | 21.35 | 320,250 |
| 2018-03-13 | ALNY | Alnylam Pharmaceuticals, Inc. | Sale | 15,000 | 149.00 | 2,235,000 |
| 2018-03-09 | ALNY | Alnylam Pharmaceuticals, Inc. | Sale | 15,000 | 129.00 | 1,935,000 |
| 2018-03-09 | ALNY | Alnylam Pharmaceuticals, Inc. | Option Ex | 15,000 | 27.28 | 409,200 |
| 2017-02-01 | ALNY | Alnylam Pharmaceuticals, Inc. | Sale | 25,000 | 39.94 | 998,500 |
| 2017-02-01 | ALNY | Alnylam Pharmaceuticals, Inc. | Option Ex | 25,000 | 31.29 | 782,250 |
| 2017-01-25 | ALNY | Alnylam Pharmaceuticals, Inc. | Sale | 15,000 | 37.95 | 569,250 |
| 2017-01-25 | ALNY | Alnylam Pharmaceuticals, Inc. | Option Ex | 15,000 | 31.39 | 470,850 |
| 2017-01-18 | ALNY | Alnylam Pharmaceuticals, Inc. | Option Ex | 15,000 | 15.91 | 238,650 |
| 2017-01-18 | ALNY | Alnylam Pharmaceuticals, Inc. | Sale | 15,000 | 37.88 | 568,275 |
| 2015-12-04 | ALNY | Alnylam Pharmaceuticals, Inc. | Option Ex | 30,000 | 14.39 | 431,850 |
| 2015-12-04 | ALNY | Alnylam Pharmaceuticals, Inc. | Sale | 30,000 | 109.00 | 3,270,000 |
| 2014-10-13 | ALNY | Alnylam Pharmaceuticals, Inc. | Sale | 110,000 | 85.00 | 9,350,000 |
| 2014-10-13 | ALNY | Alnylam Pharmaceuticals, Inc. | Option Ex | 110,000 | 7.42 | 816,750 |
| 2013-01-22 | ALNY | Alnylam Pharmaceuticals, Inc. | Buy | 4,967 | 20.13 | 99,985 |
| 2012-02-21 | ALNY | Alnylam Pharmaceuticals, Inc. | Buy | 9,302 | 10.75 | 99,996 |
| 2008-07-21 | BIIB | Biogen Inc. | Option Ex | 72,500 | 35.42 | 2,567,950 |
| 2008-07-21 | BIIB | Biogen Inc. | Sale | 72,500 | 68.00 | 4,930,000 |
| 2008-04-08 | BIIB | Biogen Inc. | Option Ex | 100,000 | 35.42 | 3,542,000 |
| 2008-04-08 | BIIB | Biogen Inc. | Sale | 76,850 | 64.20 | 4,933,616 |
| 2008-04-08 | BIIB | Biogen Inc. | Sale | 15,650 | 64.63 | 1,011,428 |
| 2008-04-08 | BIIB | Biogen Inc. | Sale | 7,500 | 64.87 | 486,525 |
| 2007-05-25 | BIIB | Biogen Inc. | Option Ex | 1,250 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Sharp Philip A (Director of Alnylam Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.